Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Recruiting × Medulloblastoma × Irinotecan × Clear all

Phase

Status

Completed 8 Active not recruiting 2 Recruiting 1 Not yet recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Colorectal Neoplasms 27 Pancreatic Neoplasms 12 Neuroblastoma 10 Stomach Neoplasms 9 Neoplasm Metastasis 9 Neoplasms 7 Rectal Neoplasms 5 Small Cell Lung Carcinoma 3 Sarcoma, Ewing 3 Rhabdomyosarcoma 3 Ovarian Neoplasms 3 Esophageal Squamous Cell Carcinoma 3 Colonic Neoplasms 3 Breast Neoplasms 3 Adenocarcinoma Of Esophagus 3 Wilms Tumor 2 Sarcoma 2 Recurrence 2 Parkinson Disease 4, Autosomal Dominant Lewy Body 2 Osteosarcoma 2 Esophageal Neoplasms 2 Endometrial Neoplasms 2 Biliary Tract Neoplasms 2 Advanced Solid Tumors 2 Adenocarcinoma 2 Uterine Neoplasms 1 Uterine Cervical Neoplasms 1 Triple Negative Breast Neoplasms 1 Stage I Mixed Cell Type Kidney Wilms Tumor 1 Refractory Solid Tumors 1

Interventions

Temozolomide 5 Cyclophosphamide 5 Etoposide 4 Radiotherapy 3 lutetium Lu 177 dotatate 2 Vincristine 2 Radiation 2 Cisplatin 2 sodium thiosulfate 1 pegfilgrastim 1 olaparib 1 ibrutinib 1 fludarabine 1 fenofibric acid 1 etoposide phosphate 1 Topotecan 1 Thalidomide 1 Tablets 1 Standard of Care 1 Specimen Handling 1 Platinum 1 ONC206 1 Methotrexate 1 Metformin 1 Magnetic Resonance Spectroscopy 1 Lomustine 1 Irinotecan 1 Hearing 1 Filgrastim 1 Exercise 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT01356290 2026-02-23

MEMMAT

Medical University of Vienna

Phase 2 Recruiting

Ependymoma, Medulloblastoma, Recurrence

Data powered by HemOnc (CC BY 4.0) Colophon ⚡